J&J Ties Up With India's Emcure For a Splash Into Branded Generics; Deal May Be Precursor To Bigger Global Presence
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - It may be a small start in India but the drugs-to-diagnostics giant Johnson & Johnson looks set for a big splash in branded generic drugs - a segment its bigger rivals like Pfizer, GlaxoSmithKline and Sanofi-Aventis have been embracing over the last few years through aggressive partnerships and acquisition of strong regional players
You may also be interested in...
Multinational Suitors Queue Up As India's Paras Pharma Valuation Shoots Above $1 Billion
MUMBAI - As prospective multinational suitors queue up to clinch a majority equity stake in Paras Pharma - a fast-growing Indian OTC and cosmetic company - leading investment bankers have questioned whether the asking price is "unreasonable and exaggerated.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).